DMARD in rheumatoid a rthritis and psoriatic arthrits. The proportions of patients who have re - ceived anti-TNF drugs in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis

نویسندگان

  • Tore K. Kvien
  • Marte S. Heiberg
چکیده

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anti-TNF Trial in Rheumatoid Arthritis with Comcomitant Therapy; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASGI = Bath Ankylosing Spondylitis Disease Global Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; DMARD

ANA = antinuclear antibody; AS = ankylosing spondylitis; ATTRACT = Anti-TNF Trial in Rheumatoid Arthritis with Comcomitant Therapy; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASGI = Bath Ankylosing Spondylitis Disease Global Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; DMARD = disease-modifying antirheumatic...

متن کامل

Pustular eruption induced by etanercept in a patient with ankylosing spondylitis: a rare side effect

Etanercept is a tumor necrosis factor alpha (TNF-a) antagonist with anti-inflammatory effects. It is used in the treatment of dermatologic and rheumatologic diseases such as rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. However, etanercept has various cutaneous and systemic side effects. Herein, we report a case of generalized...

متن کامل

DRUG EVALUATION Etanercept: a soluble TNF-α receptor in the treatment of psoriasis

10.2217/14750708.4.5.665 © 2 Among tumor necrosis factor (TNF)-α neutralizing drugs, etanercept is unique in as much as it is a recombinant, fully human, soluble form of the TNF-α receptor. Previously licensed for the treatment of adult and juvenile rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, recent double-blind, placebo-controlled, randomized trials have provided larg...

متن کامل

Adalimumab in the treatment of rheumatoid arthritis.

Adalimumab (ADA), a fully human monoclonal antibody against TNF-α is indicated for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and psoriasis. In RA, it may be prescribed in combination with methotrexate or other disease-modifying antirheumatic drugs or as monotherapy. Studies comparin...

متن کامل

Non-Hodgkin Lymphoma in Psoriatic Arthritis Treated with Sequential, Multiple Anti-TNF-α Agents: A Case Report

The introduction of drugs designed to inhibit the effects of TNF-α significantly modified the prognosis of multiple chronic inflammatory disorders, including rheumatoid arthritis (RA), psoriatic arthritis (PA), psoriasis and ankylosing spondylitis (AS). In these diseases that require long-term treatment with immunosuppressive therapies, there has always been concern that such treatments could i...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2005